{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-263540","form_type":"8-K","ticker":"KYMR","cik":"0001815442","company_name":"Kymera Therapeutics, Inc.","filed_at":"2025-11-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.561100+00:00","generated_at":"2026-05-17T00:41:16.351019+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Kymera Q3 net loss $82.2M; KT-621 Phase 1b AD data due Dec 2025","bullets":["Net loss $82.2M in Q3 2025 vs $62.5M in Q3 2024; R&D expenses rose to $74.1M.","Cash $978.7M as of Sept 30; runway into H2 2028 beyond multiple pipeline milestones.","KT-621 Phase 1b AD trial (BroADen) enrollment complete; top-line data expected Dec 2025.","KT-621 Phase 2b AD trial (BROADEN2) initiated; asthma Phase 2b (BREADTH) on track for 1Q26.","KT-579 (IRF5) IND-enabling studies completed; Phase 1 planned for early 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-263540","json":"https://secwatch.observer/filing/0001193125-25-263540.json","markdown":"https://secwatch.observer/filing/0001193125-25-263540.md","text":"https://secwatch.observer/filing/0001193125-25-263540.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1815442/000119312525263540/0001193125-25-263540-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1815442/000119312525263540/kymr-20251104.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:41:16.351019+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}